Compare Davita Inc (DVA) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Alphabet Inc Class A — how do they compare? Davita Inc trades at $231.11 (market cap $14.92B), while Alphabet Inc Class A trades at $370.37 (market cap $4.37T). The key difference: Alphabet Inc Class A is far larger — about 292.9× Davita Inc's market cap, and Alphabet Inc Class A pays a 0.24% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | GOOGL | |
|---|---|---|
Market Cap | $14.92B | $4.37T |
Sector | Health | Media |
52-Week High | $235.71 | $402.62 |
52-Week Low | $103.87 | $182.00 |
Enterprise Value | $27.47B | $4.34T |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Alphabet (GOOGL) trades at $370.92, up 5.22% with strong fundamental performance including 32.8% net income margin and consistent earnings beats. Technical indicators show neutral momentum with support at $355 and resistance at $362. The company demonstrates robust revenue growth from $350B in 2024 to $402.8B in 2025, supported by AI-driven advertising expansion and cloud services.
Outlook remains positive with 85% analyst buy ratings and $431.78 consensus target, representing 16% upside. Key risks include antitrust scrutiny and AI competition, but strong cash flow generation and YouTube subscription pricing increases provide stability. The stock offers growth exposure to AI infrastructure and digital advertising leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
